Topigen Pharmaceuticals, Respiratory Research

Synthesis and Assessment of fused β-carboline derivatives as Kappa Opioid Receptor agonist

The synthesis of 5-formyl-6-aryl-6H-indolo[3,2,1-de][1,5] naphthyridine-2-carboxylates by way of response between 1-formyl-9H-b-carbolines and cinnamaldehydes within the presence of pyrrolidine in water beneath microwave irradiation is described. Pharmacophoric modification of the formyl group provided a number of new fused-b-carboline derivatives which have been investigated for his or her k-opioid receptor (KOR) agonistic exercise.

Two compounds 4a and 4c produced considerable agonist exercise on KOR with EC50 of 46±19 nM and 134±9 nM, respectively. Furthermore, compound induced KOR signaling research advised each compounds to be extraordinarily G-protein biased agonist. The analgesic impact of 4a was validated by the rise in tail flick latency in time dependent method, which was utterly blocked by KOR selective antagonist norBNI. Furthermore, not like U50488, an unbaised full KOR agonist, 4a didn’t induce sedation. The docking of 4a with the human KOR was studied to rationalize the consequence.

The results of an alpha-2-adrenoceptor agonist, antagonist, and their mixture on the blood insulin, glucose, and glucagon concentrations in insulin delicate and dysregulated horses

Alpha-2-adrenoceptor agonists are sedatives that may trigger fluctuations in serum insulin and blood glucose (BG) concentrations in horses. The aims of this examine have been to analyze the results of detomidine and vatinoxan on BG, insulin, and glucagon concentrations in horses with and with out insulin dysregulation (ID). In a blinded cross-over design, eight horses with ID and eight horses with out ID have been assigned to every of 4 therapies: detomidine (0.02 mg/kg; DET), vatinoxan (0.2 mg/kg; VAT), detomidine + vatinoxan (DET + VAT), and saline management (SAL). Blood samples have been taken at 0, 1, 2, 4, 6, and eight h.

Change from baseline was used because the response in modelling, and the variations between therapies have been evaluated with repeated measures evaluation of covariance. P values ≤0.05 have been thought-about important. Evaluating DET vs. SAL and DET vs. DET + VAT, insulin was larger at 2 h within the non-ID group and a pair of and Four h within the ID group.

There was no distinction in insulin between SAL and DET + VAT or VAT. Evaluating DET vs. SAL, BG was larger at 1 and a pair of h then was decrease at Four h in each ID and non-ID teams. At 1 h in each teams, BG after DET + VAT was decrease than after DET however larger than after SAL. Evaluating DET vs. SAL, glucagon was decrease at 1 h within the ID group and 1 and a pair of h within the non-ID group. Vatinoxan was efficient in stopping detomidine-induced hyperglycaemia in addition to the following insulin improve in horses with ID.

The selective 5-HT2A receptor agonist 25CN-NBOH doesn’t have an effect on reversal studying in mice

Psychedelic 5-hydroxytryptamine 2A receptor (5-HT2AR) agonists are displaying promise within the therapy of psychiatric problems, comparable to treatment-resistant despair and nervousness. Human research recommend that enhanced cognitive flexibility could contribute to their medical efficacy. Each enchancment and impairment of cognitive flexibility has been reported with 5-HT2AR ligands, making the hyperlink between 5-HT2AR pharmacology and cognitive flexibility equivocal.

We examined the selective 5-HT2AR agonist 25CN-NBOH in wholesome male C57BL/6JOlaHsd mice in a touchscreen-based mouse reversal studying take a look at. No results have been noticed on acquisition of the brand new stimulus-reward contingency, studying errors, or perseverative responses throughout reversal. Our outcomes recommend that 25CN-NBOH doesn’t have an effect on reversal studying within the schedule used on this examine.

β-caryophyllene, a pure bicyclic sesquiterpene attenuates β-adrenergic agonist-induced myocardial harm in a cannabinoid receptor-2 dependent and impartial method

The downregulation of cannabinoid type-2 receptors (CB2R) have been reported in quite a few illnesses together with cardiovascular illnesses (CVDs). The activation of CB2R has been just lately emerged as an necessary therapeutic goal to mitigate myocardial harm. We examined whether or not CB2R activation can shield towards isoproterenol (ISO)-induced myocardial harm (MI) in rats. Within the current examine, we investigated the cardioprotective impact of β-caryophyllene (BCP), a naturally occurring dietary cannabinoid in rat mannequin of MI.

Rats have been pre- and co-treated with BCP (50 mg/kg, orally) twice day by day for 10 days together with subcutaneous injection of ISO (85 mg/kg) at an interval of 24 h for 2 days (9^th and 10^th days). AM630 (1 mg/kg), a CB2 receptor antagonist, was injected intraperitoneal as a pharmacological problem previous to BCP therapy to disclose CB2R-mediated cardioprotective mechanisms of BCP.

Desensitization of beta-adrenergic receptor (β-AR) signaling, receptor phosphorylation and recruitment of adapter β-arrestins have been noticed in ISO-induced MI in rats. ISO injections triggered impaired cardiac operate, elevated the degrees of serum cardiac marker enzymes, and enhanced oxidative stress markers together with altered PI3K/Akt and NrF2/Keap1/HO-1 signaling pathways.

ISO additionally promoted lysosomal dysfunction together with activation of NLRP3 inflammasomes and TLR4-NFκB/MAPK signaling and triggered rise in proinflammatory cytokines. There was a concomitant mitochondrial dysfunction adopted by the activation of endoplasmic reticulum (ER) stress-mediated Hippo signaling and intrinsic pathway of apoptosis in addition to altered autophagic flux/mTOR signaling was noticed in ISO-induced MI.

Moreover, ISO additionally triggered dyslipidemia evidenced by altered lipids, lipoproteins and lipid marker enzymes together with adjustments in ionic homeostasis malfunction. IHowever, therapy with BCP resulted in important protecting results on all biochemical and molecular parameters analyzed. The cardioprotective results have been additional strengthened by preservation of cardiomyocytes and cell organelles as noticed in histopathological and ultrastructural research.

Integrin Antagonists 27
MBS3845333-5x100mg	MyBiosource	5x100mg	EUR 20235

Integrin Antagonists 27
T15584-10mg	TargetMol Chemicals	10mg	Ask for price
Description: Integrin Antagonists 27

Integrin Antagonists 27
T15584-1g	TargetMol Chemicals	1g	Ask for price
Description: Integrin Antagonists 27

Integrin Antagonists 27
T15584-1mg	TargetMol Chemicals	1mg	Ask for price
Description: Integrin Antagonists 27

Integrin Antagonists 27
T15584-50mg	TargetMol Chemicals	50mg	Ask for price
Description: Integrin Antagonists 27

Integrin Antagonists 27
T15584-5mg	TargetMol Chemicals	5mg	Ask for price
Description: Integrin Antagonists 27

Integrin-Antagonists-27
MBS131187-100mg	MyBiosource	100mg	EUR 1065

Integrin-Antagonists-27
MBS131187-500mg	MyBiosource	500mg	EUR 2775

Glucagon receptor antagonists-2
HY-50158	MedChemExpress	5mg	EUR 293.29

Glucagon receptor antagonists-3
HY-50159	MedChemExpress	5mg	EUR 293.29

Glucagon receptor antagonists-1
HY-10036	MedChemExpress	10mg	EUR 346.33

Glucagon receptor antagonists-5
HY-128781	MedChemExpress	Get quote	Ask for price
Description: Glucagon receptor antagonists-5 (compound 13K) is a potent and orally bioavailable indazole-based glucagon receptor antagonist (Ki=32 nM). Glucagon receptor antagonists-5 has potential for the treatment of type 2 diabetes mellitus (T2DM)[1].

Glucagon receptor antagonists-1
MBS5753198-50mg	MyBiosource	50mg	EUR 1505

Glucagon receptor antagonists-1
MBS5753198-5x50mg	MyBiosource	5x50mg	EUR 6615

Glucagon receptor antagonists-2
MBS5753199-50mg	MyBiosource	50mg	EUR 1215

Glucagon receptor antagonists-2
MBS5753199-5x50mg	MyBiosource	5x50mg	EUR 5325

Glucagon receptor antagonists-3
MBS5753200-50mg	MyBiosource	50mg	EUR 1215

Glucagon receptor antagonists-3
MBS5753200-5x50mg	MyBiosource	5x50mg	EUR 5325

Glucagon receptor antagonists-5
MBS5766728-5mg	MyBiosource	5mg	EUR 915

Glucagon receptor antagonists-5
MBS5766728-5x5mg	MyBiosource	5x5mg	EUR 3970

Glucagon receptor antagonists-1
MBS386767-100mg	MyBiosource	100mg	EUR 2910

Glucagon receptor antagonists-1
MBS386767-10mg	MyBiosource	10mg	EUR 545

Glucagon receptor antagonists-1
MBS386767-50mg	MyBiosource	50mg	EUR 1490

Glucagon receptor antagonists-1
MBS386767-5mg	MyBiosource	5mg	EUR 335

Glucagon receptor antagonists-1
MBS386767-5x100mg	MyBiosource	5x100mg	EUR 13085

Glucagon receptor antagonists-2
MBS386768-100mg	MyBiosource	100mg	EUR 2910

Glucagon receptor antagonists-2
MBS386768-10mg	MyBiosource	10mg	EUR 545

Glucagon receptor antagonists-2
MBS386768-50mg	MyBiosource	50mg	EUR 1490

Glucagon receptor antagonists-2
MBS386768-5mg	MyBiosource	5mg	EUR 335

Glucagon receptor antagonists-2
MBS386768-5x100mg	MyBiosource	5x100mg	EUR 13085

Glucagon receptor antagonists-3
MBS386769-100mg	MyBiosource	100mg	EUR 2910

Glucagon receptor antagonists-3
MBS386769-10mg	MyBiosource	10mg	EUR 545

Glucagon receptor antagonists-3
MBS386769-50mg	MyBiosource	50mg	EUR 1490

Glucagon receptor antagonists-3
MBS386769-5mg	MyBiosource	5mg	EUR 335

Glucagon receptor antagonists-3
MBS386769-5x100mg	MyBiosource	5x100mg	EUR 13085

Glucagon receptor antagonists-1
T11413-10mg	TargetMol Chemicals	10mg	Ask for price
Description: Glucagon receptor antagonists-1

Glucagon receptor antagonists-1
T11413-1g	TargetMol Chemicals	1g	Ask for price
Description: Glucagon receptor antagonists-1

Glucagon receptor antagonists-1
T11413-1mg	TargetMol Chemicals	1mg	Ask for price
Description: Glucagon receptor antagonists-1

Glucagon receptor antagonists-1
T11413-50mg	TargetMol Chemicals	50mg	Ask for price
Description: Glucagon receptor antagonists-1

Glucagon receptor antagonists-1
T11413-5mg	TargetMol Chemicals	5mg	Ask for price
Description: Glucagon receptor antagonists-1

Glucagon receptor antagonists-2
T11414-10mg	TargetMol Chemicals	10mg	Ask for price
Description: Glucagon receptor antagonists-2

Glucagon receptor antagonists-2
T11414-1g	TargetMol Chemicals	1g	Ask for price
Description: Glucagon receptor antagonists-2

Glucagon receptor antagonists-2
T11414-1mg	TargetMol Chemicals	1mg	Ask for price
Description: Glucagon receptor antagonists-2

Glucagon receptor antagonists-2
T11414-50mg	TargetMol Chemicals	50mg	Ask for price
Description: Glucagon receptor antagonists-2

Glucagon receptor antagonists-2
T11414-5mg	TargetMol Chemicals	5mg	Ask for price
Description: Glucagon receptor antagonists-2

Glucagon receptor antagonists-3
T11415-10mg	TargetMol Chemicals	10mg	Ask for price
Description: Glucagon receptor antagonists-3

Glucagon receptor antagonists-3
T11415-1g	TargetMol Chemicals	1g	Ask for price
Description: Glucagon receptor antagonists-3

Glucagon receptor antagonists-3
T11415-1mg	TargetMol Chemicals	1mg	Ask for price
Description: Glucagon receptor antagonists-3

Glucagon receptor antagonists-3
T11415-50mg	TargetMol Chemicals	50mg	Ask for price
Description: Glucagon receptor antagonists-3

Glucagon receptor antagonists-3
T11415-5mg	TargetMol Chemicals	5mg	Ask for price
Description: Glucagon receptor antagonists-3

Glucagon receptor antagonists-5
T11416-10mg	TargetMol Chemicals	10mg	Ask for price
Description: Glucagon receptor antagonists-5

Glucagon receptor antagonists-5
T11416-1g	TargetMol Chemicals	1g	Ask for price
Description: Glucagon receptor antagonists-5

Glucagon receptor antagonists-5
T11416-1mg	TargetMol Chemicals	1mg	Ask for price
Description: Glucagon receptor antagonists-5

Glucagon receptor antagonists-5
T11416-50mg	TargetMol Chemicals	50mg	Ask for price
Description: Glucagon receptor antagonists-5

Glucagon receptor antagonists-5
T11416-5mg	TargetMol Chemicals	5mg	Ask for price
Description: Glucagon receptor antagonists-5

glucagon receptor antagonists 1
A3435-10	ApexBio	10 mg	EUR 475.2
Description: GPCR/G protein|Glucagon Receptor

glucagon receptor antagonists 1
A3435-5	ApexBio	5 mg	EUR 264.8
Description: GPCR/G protein|Glucagon Receptor

glucagon receptor antagonists 1
A3435-50	ApexBio	50 mg	EUR 1624.8
Description: GPCR/G protein|Glucagon Receptor

glucagon receptor antagonists 2
A3436-10	ApexBio	10 mg	EUR 509.6
Description: GPCR/G protein|Glucagon Receptor

glucagon receptor antagonists 2
A3436-5	ApexBio	5 mg	EUR 278.4
Description: GPCR/G protein|Glucagon Receptor

glucagon receptor antagonists 3
A3437-10	ApexBio	10 mg	EUR 509.6
Description: GPCR/G protein|Glucagon Receptor

glucagon receptor antagonists 3
A3437-5	ApexBio	5 mg	EUR 278.4
Description: GPCR/G protein|Glucagon Receptor

glucagon receptor antagonists 3
A3437-5.1	ApexBio	10 mM (in 1mL DMSO)	EUR 598.8
Description: highly potent glucagon receptor antagonist

Rat growth hormone antagonists (G119R)
MBS400126-001mg	MyBiosource	0.01mg	EUR 185

Rat growth hormone antagonists (G119R)
MBS400126-005mg	MyBiosource	0.05mg	EUR 275

Rat growth hormone antagonists (G119R)
MBS400126-01mg	MyBiosource	0.1mg	EUR 370

Rat growth hormone antagonists (G119R)
MBS400126-05mg	MyBiosource	0.5mg	EUR 990

Rat growth hormone antagonists (G119R)
MBS400126-1mg	MyBiosource	1mg	EUR 1690

Calcium-Sensing Receptor Antagonists I
A3275-10	ApexBio	10 mg	EUR 316
Description: GPCR/G protein|CaSR

Calcium-Sensing Receptor Antagonists I
A3275-100	ApexBio	100 mg	EUR 1239.2
Description: GPCR/G protein|CaSR

Calcium-Sensing Receptor Antagonists I
A3275-5.1	ApexBio	10 mM (in 1mL DMSO)	EUR 672
Description: Calcium-Sensing Receptor Antagonists I is antagonists of calcium-sensing parathyroid hormone receptors.

Calcium-Sensing Receptor Antagonists I
HY-50713	MedChemExpress	10mM/1mL	EUR 595.25
Description: Calcium-Sensing Receptor Antagonists I is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

Calcium-Sensing Receptor Antagonists I
MBS5752851-100mg	MyBiosource	100mg	EUR 1020

Calcium-Sensing Receptor Antagonists I
MBS5752851-5x100mg	MyBiosource	5x100mg	EUR 4435

Calcium-Sensing Receptor Antagonists I
MBS3840790-100mg	MyBiosource	100mg	EUR 985

Calcium-Sensing Receptor Antagonists I
MBS3840790-10mg	MyBiosource	10mg	EUR 290

Calcium-Sensing Receptor Antagonists I
MBS3840790-50mg	MyBiosource	50mg	EUR 635

Calcium-Sensing Receptor Antagonists I
MBS3840790-5x100mg	MyBiosource	5x100mg	EUR 4420

Calcium-Sensing Receptor Antagonists I
T10665-10mg	TargetMol Chemicals	10mg	Ask for price
Description: Calcium-Sensing Receptor Antagonists I

Calcium-Sensing Receptor Antagonists I
T10665-1g	TargetMol Chemicals	1g	Ask for price
Description: Calcium-Sensing Receptor Antagonists I

Calcium-Sensing Receptor Antagonists I
T10665-1mg	TargetMol Chemicals	1mg	Ask for price
Description: Calcium-Sensing Receptor Antagonists I

Calcium-Sensing Receptor Antagonists I
T10665-50mg	TargetMol Chemicals	50mg	Ask for price
Description: Calcium-Sensing Receptor Antagonists I

Calcium-Sensing Receptor Antagonists I
T10665-5mg	TargetMol Chemicals	5mg	Ask for price
Description: Calcium-Sensing Receptor Antagonists I

HighQC™ Human Mobilized Peripheral Blood CD34+ Stem/Progenitor Cells; CXCR4 Antagonists
ABC-SC0090T	AcceGen	1 vial	Ask for price
Description: CD34+ stem cells are multipotent and can give rise to all cell types in blood. CD34 cells are most known for its expression on hematopoietic progenitor cells found in bone marrow and cord blood. While compromising only 1.5% of bone marrow mononuclear cell population, CD34 stem cells are responsible for all lymphohematopoietic lineages and are now commonly used clinically as they have been shown to provide long-term durable donor-derived host lymphohematopoietic reconstitution.Donors are injected with CXCR4 antagonists, which stimulates the bone marrow to produce a large number of hematopoietic and progenitor stem cells and mobilizes them into the peripheral blood stream.CD34+ cells are isolated using positive immunomagnetic cell separation procedures from a mobilized leukapheresis collection.

HighQC™ Human Mobilized Peripheral Blood CD34+ Stem/Progenitor Cells; G-CSF And CXCR4 Antagonists
ABC-SC0091T	AcceGen	1 vial	Ask for price
Description: CD34 is most commonly associated with expression on hematopoietic progenitor cells found in bone marrow and cord blood. While compromising only 1.5% of bone marrow mononuclear cell population, CD34 stem cells are multipotent and responsible for all lymphohematopoietic lineages. These cells are now commonly used clinically as they have been shown to provide long-term durable donor-derived host lymphohematopoietic reconstitution.Donors are injected with a combination of CXCR4 antagonists and G-CSF, which stimulates the bone marrow to produce a large number of hematopoietic and progenitor stem cells and mobilizes them into the peripheral blood stream.CD34+ cells are isolated using positive immunomagnetic cell separation procedures from a mobilized leukapheresis collection.

TSHR antagonist S37
MBS5767786-10mg	MyBiosource	10mg	EUR 275

TSHR antagonist S37
MBS5767786-2mg	MyBiosource	2mg	EUR 175

TSHR antagonist S37
MBS5767786-5mg	MyBiosource	5mg	EUR 210

TSHR antagonist S37
T13216-10mg	TargetMol Chemicals	10mg	Ask for price
Description: TSHR antagonist S37

TSHR antagonist S37
T13216-1g	TargetMol Chemicals	1g	Ask for price
Description: TSHR antagonist S37

TSHR antagonist S37
T13216-1mg	TargetMol Chemicals	1mg	Ask for price
Description: TSHR antagonist S37

TSHR antagonist S37
T13216-50mg	TargetMol Chemicals	50mg	Ask for price
Description: TSHR antagonist S37

TSHR antagonist S37
T13216-5mg	TargetMol Chemicals	5mg	Ask for price
Description: TSHR antagonist S37

TSHR antagonist S37b
HY-129995	MedChemExpress	10 mg	EUR 2597.44
Description: TSHR antagonist S37b is the less effective enantiomer of TSHR antagonist S37a (HY-129995A). TSHR antagonist S37b shows only a minor effect for thyrotropin receptor (TSHR) inhibition. TSHR antagonist S37b can be used for the research of thyroid function[1].

TSHR antagonist S37a
HY-129995A	MedChemExpress	10 mg	EUR 2597.44
Description: TSHR antagonist S37a is a highly selective thyrotropin receptor (TSHR) antagonist, with potential for the treatment of Graves' orbitopathy[1].

TSHR antagonist S37b
MBS5785346-10mg	MyBiosource	10mg	EUR 965

TSHR antagonist S37b
MBS5785346-25mg	MyBiosource	25mg	EUR 1795

TSHR antagonist S37b
MBS5785346-5mg	MyBiosource	5(mg	EUR 460

TSHR antagonist S37a
MBS5767787-100mg	MyBiosource	100mg	EUR 4060

TSHR antagonist S37a
MBS5767787-10mg	MyBiosource	10mg	EUR 965

TSHR antagonist S37a
MBS5767787-25mg	MyBiosource	25mg	EUR 1795

TSHR antagonist S37a
MBS5767787-50mg	MyBiosource	50mg	EUR 2725

TSHR antagonist S37a
MBS5767787-5x100mg	MyBiosource	5x100mg	EUR 18115

TSHR antagonist S37a
T13217-10mg	TargetMol Chemicals	10mg	Ask for price
Description: TSHR antagonist S37a

TSHR antagonist S37a
T13217-1g	TargetMol Chemicals	1g	Ask for price
Description: TSHR antagonist S37a

TSHR antagonist S37a
T13217-1mg	TargetMol Chemicals	1mg	Ask for price
Description: TSHR antagonist S37a

TSHR antagonist S37a
T13217-50mg	TargetMol Chemicals	50mg	Ask for price
Description: TSHR antagonist S37a

TSHR antagonist S37a
T13217-5mg	TargetMol Chemicals	5mg	Ask for price
Description: TSHR antagonist S37a

TSHR antagonist S37b
T38226-10mg	TargetMol Chemicals	10mg	Ask for price
Description: TSHR antagonist S37b

TSHR antagonist S37b
T38226-1g	TargetMol Chemicals	1g	Ask for price
Description: TSHR antagonist S37b

TSHR antagonist S37b
T38226-1mg	TargetMol Chemicals	1mg	Ask for price
Description: TSHR antagonist S37b

TSHR antagonist S37b
T38226-50mg	TargetMol Chemicals	50mg	Ask for price
Description: TSHR antagonist S37b

TSHR antagonist S37b
T38226-5mg	TargetMol Chemicals	5mg	Ask for price
Description: TSHR antagonist S37b

Interleukin-1 receptor antagonist, 26-177 aa, Human, E Coli
MBS203091-002mg	MyBiosource	0.02mg	EUR 215

Interleukin-1 receptor antagonist, 26-177 aa, Human, E Coli
MBS203091-01mg	MyBiosource	0.1mg	EUR 340

Interleukin-1 receptor antagonist, 26-177 aa, Human, E Coli
MBS203091-05mg	MyBiosource	0.5mg	EUR 765

Interleukin-1 receptor antagonist, 26-177 aa, Human, E Coli
MBS203091-5x05mg	MyBiosource	5x0.5mg	EUR 3195

Rabbit Polyclonal antibody to IL1ra antagonist (interleukin 1 receptor antagonist)
TA308778	Origene Technologies GmbH	100 µl	Ask for price

Rat Interleukin 17 Receptor antagonist
E01A14186	BlueGene	96T	EUR 700
Description: ELISA

Rat Interleukin 17 Receptor antagonist
E02I0761-48wellsplate	BlueGene	48 wells plate	EUR 280

Rat Interleukin 17 Receptor antagonist
E02I0761-96wellsplate	BlueGene	96 wells plate	EUR 405

Goat Interleukin 17 Receptor antagonist
E01A49095	BlueGene	96T	EUR 700
Description: ELISA

Goat Interleukin 17 Receptor antagonist
E06I0761-48wellsplate	BlueGene	48 wells plate	EUR 280

Goat Interleukin 17 Receptor antagonist
E06I0761-96wellsplate	BlueGene	96 wells plate	EUR 405

Mouse Interleukin 17 Receptor antagonist
E01A22928	BlueGene	96T	EUR 700
Description: ELISA

Sheep Interleukin 17 Receptor antagonist
E01A101388	BlueGene	96T	EUR 700
Description: ELISA

Human Interleukin 17 Receptor antagonist
E01A5435	BlueGene	96T	EUR 700
Description: ELISA

Mouse Interleukin 17 Receptor antagonist
E03I0761-48wellsplate	BlueGene	48 wells plate	EUR 280

Mouse Interleukin 17 Receptor antagonist
E03I0761-96wellsplate	BlueGene	96 wells plate	EUR 405

Human Interleukin 17 Receptor antagonist
E01I0761-48wellsplate	BlueGene	48 wells plate	EUR 280

Human Interleukin 17 Receptor antagonist
E01I0761-96wellsplate	BlueGene	96 wells plate	EUR 405

Sheep Interleukin 17 Receptor antagonist
E14I0761-48wellsplate	BlueGene	48 wells plate	EUR 280

Sheep Interleukin 17 Receptor antagonist
E14I0761-96wellsplate	BlueGene	96 wells plate	EUR 405

Interleukin 1 Receptor Antagonist (IL-1Ra)
MBS634948-002mg	MyBiosource	0.02mg	EUR 405

Interleukin 1 Receptor Antagonist (IL-1Ra)
MBS634948-01mg	MyBiosource	0.1mg	EUR 610

Interleukin 1 Receptor Antagonist (IL-1Ra)
MBS634948-5x01mg	MyBiosource	5x0.1mg	EUR 2600

Mouse interleukin 1 receptor antagonist
MBS400078-001mg	MyBiosource	0.01mg	EUR 170

Mouse interleukin 1 receptor antagonist
MBS400078-005mg	MyBiosource	0.05mg	EUR 220

Mouse interleukin 1 receptor antagonist
MBS400078-01mg	MyBiosource	0.1mg	EUR 565

Mouse interleukin 1 receptor antagonist
MBS400078-1mg	MyBiosource	1mg	EUR 845

Human Interleukin-1 receptor antagonist
90170-A	BPS Bioscience	20 µg	EUR 130
Description: Recombinant IL-1RA is a disulfide-linked monomer protein consisting of 153 amino acid residues, and migrates as an approximately 17 kDa protein under non-reducing and reducing conditions in SDS-PAGE. Optimized DNA sequence encoding Human interleukin-1 receptor antagonist mature chain was expressed in E. coli. _x000D__x000D_

Human Interleukin-1 receptor antagonist
90170-B	BPS Bioscience	100 µg	EUR 205
Description: Recombinant IL-1RA is a disulfide-linked monomer protein consisting of 153 amino acid residues, and migrates as an approximately 17 kDa protein under non-reducing and reducing conditions in SDS-PAGE. Optimized DNA sequence encoding Human interleukin-1 receptor antagonist mature chain was expressed in E. coli. _x000D__x000D_

Monkey Interleukin 17 Receptor antagonist
E01A75242	BlueGene	96T	EUR 700
Description: ELISA

Canine Interleukin 17 Receptor antagonist
E01A66525	BlueGene	96T	EUR 700
Description: ELISA

Apparently, therapy with AM630, a CB2R antagonist was noticed to abrogate the protecting results of BCP on the biochemical and molecular parameters besides hyperlipidemia and ionic homeostasis in ISO-induced MI in rats. The current examine findings display that BCP possess the potential to guard myocardium towards ISO-induced MI in a CB2-dependent and impartial method.